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AbstrACt
Introduction Acute gastroenteritis (AGE) is a common 
and burdensome condition that affects millions of children 
worldwide each year. Currently available strategies 
are limited to symptomatic management, treatment 
and prevention of dehydration and infection control; no 
disease-modifying interventions exist. Probiotics, defined 
as live microorganisms beneficial to the host, have shown 
promise in improving AGE outcomes, but existing studies 
have sufficient limitations such that the use of probiotics 
cannot currently be recommended with confidence. Here 
we present the methods of a large, rigorous, randomised, 
double-blind placebo-controlled study to assess the 
effectiveness and side effect profile of Lactobacillus 
rhamnosus GG (LGG) (ATCC 53103) in children with AGE.
Methods and analysis The study is being conducted in 
10 US paediatric emergency departments (EDs) within 
the federally funded Pediatric Emergency Care Applied 
Research Network, in accordance with current SPIRIT and 
CONSORT statement recommendations. We will randomise 
970 children presenting to participating EDs with AGE to 
either 5 days of treatment with LGG (1010colony-forming 
unit twice a day) or placebo between July 2014 to 
December 2017. The main outcome is the occurrence of 
moderate-to-severe disease over time, as defined by the 
Modified Vesikari Scale. We also record adverse events and 
side effects related to the intervention. We will conduct 
intention-to-treat analyses and use an enrichment design 
to restore the statistical power in case the presence of a 
subpopulation with a substantially low treatment effect is 
identified.
Ethics and dissemination Institutional review board 
approval has been obtained at all sites, and data and 
material use agreements have been established between 
the participating sites. The results of the trial will be 
published in peer-reviewed journals. A deidentified public 
data set will be made available after the completion of all 
study procedures.
trial registration number NCT01773967.
IntroduCtIon
Acute gastroenteritis (AGE) is a leading cause 
of malnutrition and death worldwide.1 Though 
rarely fatal in North America, ~48 million 
people in the USA contract AGE, and 128 000 
are hospitalised annually.2 Although the 
incidence of rotavirus infection in the USA 
has decreased since the introduction of the 
vaccine in 2006,3 norovirus is now the leading 
cause of medically attended paediatric AGE 
in this country.4 Unfortunately, current inter-
ventions are limited to rehydration, symp-
tomatic management and supportive care 
and prevention of severe dehydration and 
secondary infections.5–8
Probiotics, defined as live microorganisms 
that when administered in adequate amounts 
are intended to confer health benefits on the 
recipients,9 10 represent a novel approach to 
improved management of paediatric AGE. 
strengths and limitations of this study
 ► This is a large multicentre randomised, double-
blind, placebo-controlled trial in a diverse and 
geographically varied US population of children with 
gastroenteritis.
 ► We perform independent laboratory product testing 
to assess probiotic viability, dosing and purity.
 ► We use a statistical enrichment design to restore 
the statistical power if a subpopulation with a 
substantially low treatment effect is identified.
 ► Outcome is based on parental report of symptoms 
rather than direct observation
 ► Enrolment is limited to day and evening hours only, 
when research personnel is available.
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Probiotics are generally considered to be safe, easily 
administered and hypothesised to modulate disease 
processes.11 Meta-analyses of various probiotic products 
have reported reduced symptom durations in children 
with AGE who have been treated with these agents. 
However, the studies included in these analyses have 
had important methodological limitations such as small 
sample sizes, lack of probiotic quality control, outcomes 
that are of minimal relevance to patients and their fami-
lies and unclear randomisation, allocation concealment 
and blinding and attrition biases.12–15 Remarkably, few 
studies of probiotics have evaluated outpatients, a group 
that represents the preponderance of AGE episodes in the 
USA,16–18 and only one small study has evaluated probi-
otics in children with AGE presenting to a US emergency 
department (ED), where no benefit was demonstrated.19
Given the lack of adequate efficacy and safety evidence, 
most guidelines do not endorse the use of probiotics in 
paediatric AGE.12 15 20–23 However, the European Society 
of Pediatric Gastroenterology, Hepatology and Nutri-
tion has offered a ‘strong’ recommendation in support 
of specific probiotics to treat previously healthy chil-
dren with AGE, despite their acknowledgement of the 
‘low quality of the evidence’.24 Furthermore, probiotic 
manufacturers aggressively market probiotics citing 
health claims that have not been supported by rigorous 
research,25–28 and the US market for digestive health 
enzymes, prebiotics and probiotics was estimated at 
US$495 million in 2015 and was expected to grow at 
an annual rate of 13%.29 Despite these concerns about 
their value, and issues surrounding safety and regula-
tory oversight,30–32 parents of patients with AGE often 
administer probiotics to their children without guid-
ance from medical professionals.9 22 We are there-
fore concerned that the consumption of probiotics is 
increasing without adequate evidence to support their 
use, which underscores the necessity of conducting 
a definitive trial. There is strong consensus that an 
adequately powered randomised controlled trial (RCT), 
using a well-defined probiotic agent and comprehensive 
and clinically sensible validated outcome measures in a 
clinically relevant patient population will provide much 
needed clarity to this field.12 15 33–35
Here, we report on the methodology of a double-blind 
placebo-controlled pragmatic RCT ( ClinicalTrials. gov: 
NCT01773967), using Lactobacillus rhamnosus GG (LGG) 
(ATCC 53103), the most available and studied probi-
otic in the USA as the intervention.36 37 The research is 
supported by funding from the Eunice Kennedy Shriver 
National Institute of Child Health and Human Develop-
ment (NICHD R01HD071915) and is conducted under 
the oversight of the Food and Drug Administration 
(FDA investigational new drug 12371), in 10 US EDs 
within the federally funded Pediatric Emergency Care 
Applied Research Network (PECARN). The objectives 
of this double-blind placebo-controlled RCT are to (1) 
determine if, compared with placebo, LGG reduces the 
severity of AGE episodes in children aged 3–48 months 
presenting to an ED with AGE and (2) determine the 
safety and side effect profile of LGG in children with 
AGE.
We hypothesise that (1) in children with AGE, LGG 
will be associated with a clinically meaningful decrease 
in the proportion of children suffering from a moder-
ate-to-severe episode of AGE defined by a validated Modi-
fied Vesikari Scale (MVS) score of ≥9, compared with 
placebo, and (2) LGG will not be associated with serious 
adverse events and will have a similar rate of side effects 
(eg, bloating and fever) compared with placebo-treated 
children.
MEthods And AnAlysIs
overview
This is a double-blind, 10-centre, paediatric ED-based 
RCT conducted by the PECARN. Children aged 91 days 
to <48 months who present to a participating ED between 
July 2014 to December 2017 will be assessed for eligibility, 
approached for informed consent and randomised to 
receive 5 days of a probiotic (LGG 1010 colony-forming 
unit (CFU) twice a day) or placebo. Physicians, patients, 
study personnel and outcome assessors are blinded to 
the intervention. LGG and the placebo are administered 
twice daily. The study will be conducted and reported 
according to the most recent SPIRIT and CONSORT 
statement recommendations.38–40
setting
Patients are being recruited at 10 US paediatric EDs 
in PECARN (St. Louis Children’s Hospital (St. Louis, 
Missouri, lead site), Lurie Children’s Hospital (Chicago, 
Illinois), Cincinnati Children’s Hospital Medical Center 
(Cincinnati, Ohio), Children’s Hospital of New York-Pres-
byterian (New York City, New York), Hasbro Children’s 
Hospital (Providence, Rhode Island), Children’s Hospital 
of Michigan (Detroit, Michigan), UC Davis Medical 
Center (Sacramento, California), CS Mott Children’s 
Hospital (Ann Arbor, Michigan) and the University of New 
Mexico Children’s Hospital (Albuquerque, New Mexico). 
Each centre has a strong research infrastructure and 
successfully participated in multicentre ED-based trials. 
Together the sites serve a large and diverse patient popu-
lation. PECARN, the umbrella collaborative network, is 
the first federally funded paediatric research network 
in the USA and has an extensive record of successful 
multicentre research41 The PECARN Data Coordinating 
Center (DCC), based at the University of Utah, is respon-
sible for data management and data analysis. An indepen-
dent Data Safety Monitoring Board (DSMB) composed 
of specialists in paediatric infectious diseases, paediatric 
gastroenterology, paediatric emergency medicine and 
biostatistics was formed to review enrolment, study proce-
dures, case report form completion, data quality, loss to 
follow-up, drop-in rate and interim safety and efficacy 
results.
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Inclusion criteria and rationale
1. Presence of diarrhoea: defined as ≥3 watery stools in 
the 24 hours prior to assessment,42 with or without 
vomiting (vomiting alone, which may be the sentinel 
sign of AGE, could also represent non-infectious 
illnesses and is therefore not a sufficient criterion to 
qualify for eligibility).
2. Duration of vomiting or diarrhea ≤7 days: as we are focus-
ing on acute diarrhoea, which typically is of less than 
7 days’ duration.18 It is unclear if probiotics are useful 
in the early or later stages of AGE,19 our enrichment 
design will allow for adaptive randomisation if a par-
ticular group is more likely to benefit from treatment.
3. Age 91 days–<48 months: AGE severity and frequency 
are greatest among young children,43 including those 
who visit North American EDs.17 44 45
4. Symptoms consistent with AGE per treating physician: this 
is to ensure that only children with a presumptive 
diagnosis of AGE are included in the study.
Exclusion criteria and rationale
1. Presence of an indwelling vascular access line or structural 
heart disease: potential bacteraemia risk with 
intervention.46
2. Receiving immunosuppressive therapy, or history of 
immunodeficiency: potential bacteraemia risk with 
intervention.47
3. Haematochezia: (studies show little efficacy of 
probiotics in children with bacterial AGE, and visible 
blood in the stool is a marker for such pathogens).48 49
4. Chronic gastrointestinal problems (eg, short gut 
syndrome and inflammatory bowel disease): diarrhoea 
in such children is more likely to be related to non-
infectious causes.
5. Critically ill patients or patients admitted to the intensive 
care unit: these patients are at risk of invasive disease, 
and their ability to comply with an oral intervention 
might be limited.
6. Household member with an indwelling vascular access 
line, on immunosuppressive therapy or with a known 
immunodeficiency: risk for invasive disease if there is 
intrahousehold dissemination of the LGG (note that 
this exclusion does not extend to household contacts 
who use a short course (<7 days) of oral steroids or 
are using inhaled steroids).
7. Bilious emesis: might indicate a diagnosis other than 
AGE.
8. Probiotic use (supplement) in the preceding 2 weeks: 
confounding risk; consumption of foods containing 
probiotics will not result in exclusion as they are 
ubiquitous.
9. Previously enrolled in this trial: to ensure that the 
observations are independent.
10. Daily telephone follow-up not possible while symptomatic: 
avoid loss to follow-up because of travel plans or 
language barrier.
11. Allergy to Lactobacillus or microcrystalline cellulose 
(MCC): contents of capsule and placebo.
12. Allergy to beta-lactam antibiotics, erythromycin and 
clindamycin: these antibiotics might be used in the 
event of LGG extraintestinal dissemination.
Children taking antibiotics will not be excluded because 
probiotics remain viable when given concomitantly with 
antibiotics, and the survival of the active bacterial strains 
is not diminished.50
Participant allocation
Sequence generation
The PECARN DCC produced randomisation lists, strat-
ified by study site and duration of symptoms, using 
random number-generating software. The lists were sent 
to the central pharmacy (Cincinnati Children’s Hospital 
Medical Center) that prepares consecutively numbered 
study kits according to the randomisation schedule. 
These are sent by courier to the clinical sites where they 
are stored in the research support pharmacies.
Allocation concealment
Randomisation was performed at the DCC using random 
block sizes with a 1:1 allocation ratio. Stratifying by clin-
ical site ensures that variations (eg, site-specific practice 
patterns and gastrointestinal pathogens) are comparably 
distributed across treatment arms. Only the DCC retains 
the randomisation code. Unblinding can be requested 
by treating medical personnel in case of an emergency 
requiring such information.
Implementation
 Potentially eligible patients are identified by triage nurses 
at each site who contact the research assistant (RA). The 
RA then (1) screens patients for eligibility, (2) maintains 
a log of all screened patients, (3) discusses the details of 
the study with the caregivers of all eligible children, (4) 
obtains consent, (5) enrols children, (6) consecutively 
assigns a patient identification number, (7) randomises 
the patient (using a web-based system: www. randomize. 
net), (8) collects baseline demographic clinical vari-
ables and (9) in conjunction with the treating physician, 
completes data collection forms.
Intervention
LGG and placebo capsule contents
LGG, ATCC 53103 is supplied in a gelatin capsule 
containing 1010 CFU LGG. Each LGG capsule contains 
75 mg of LGG and 250 mg of MCC, an inert ingredient. 
The placebo capsules contain only MCC (325 mg). Each 
capsule is wrapped in double foil to protect it against 
light, air and moisture. Blister packs are labelled with the 
lot number. LGG and placebo capsules and powder are 
identical in appearance, taste, texture and odour. LGG 
capsules and placebo capsules have active Drug Master 
Files at the FDA (BB-MF 213 668 and MF2 13 646, respec-
tively). The dose and duration of therapy are based on 
the currently available evidence.51–63
ED intervention
The patient’s nurse administers the first dose of either 
LGG (1010 CFU/dose) or placebo on site by sprinkling 
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the capsule’s contents into 30 mL of room temperature, 
non-carbonated liquid. The RA provides caregivers with 
verbal and written instructions regarding (1) study drug 
administration; (2) completion of study forms; (3) what 
and how much fluid to drink; (4) criteria for seeing a 
healthcare practitioner or returning to the ED; and (5) 
standardised AGE discharge instructions and letter to 
their primary care provider explaining the study. All 
other aspects of medical care will be at the discretion of 
the treating physician.
Home intervention
All patients consume one capsule of LGG or placebo, 
based on randomisation, every 12 hours for 5 days (1010 
CFU twice daily × 5 days, for a total of nine home doses). 
Patients receive the medication at meal time, mixed with 
30 mL of a room temperature non-carbonated liquid 
and ingested immediately to optimise probiotic viability. 
Oral fluid therapy is encouraged according to established 
guidelines.21 The study protocol is continued in the subset 
of children (estimated <5%) who are hospitalised.18 Also, 
caregivers are provided with a letter to share with their 
primary care provider (in case they visit their provider 
during the course of the study). The letter describes the 
study and the care plan, and it includes site investigator’s 
contact information and the importance of adhering to 
the study protocol. Patients may withdraw from the study 
at any time based on their or their physician’s discre-
tion; however, efforts will be made to proceed with safety 
follow-up, and the subjects will be included in the inten-
tion-to-treat (ITT) analysis.
Stool sample testing
Stool samples (swab or bulk stool, as available) from 
all enrolled children are collected, frozen and sent to 
Washington University – St. Louis Children’s Hospital 
Virology Laboratory and tested with multiplex PCR 
using the Luminex xTag Gastrointestinal Pathogen Panel 
(Luminex, Austin, Texas, USA), which identifies the 
following organisms (and specific bacterial loci): viruses: 
norovirus (GI and GII), adenovirus F 40/41 and rotavirus 
(A); bacteria: Escherichia coli O157, enterotoxigenic E. coli 
(lt/st), Shiga toxin-producing E. coli (stx1/stx2), Vibrio 
cholerae, Shigella spp., Salmonella spp., Campylobacter spp., 
Yersinia enterocolitica and Clostridium difficile (tcd A/B); and 
parasites: Cryptosporidium spp., Giardia spp. and Entamoeba 
histolytica.
In addition, St. Louis Children’s Hospital and the 
New Mexico Children’s Hospital collect and freeze bulk 
stool specimens in the acute phase (within 24 hours of 
presentation) and following resolution (14 days after 
presentation) using a home stool collection protocol. 
The protocol consists of providing the family with a spec-
imen collection kit, gel packs and an insulated envelope 
at enrolment. When the specimen is ready for collec-
tion, a courier retrieves the specimen and cool pack at 
the patient’s home and delivers it to a logistics collection 
centre. The stools are frozen on receipt in St. Louis and 
Albuquerque, and then stored in the Tarr Laboratory at 
Washington University at −80°C for future testing.
Data Collection
All caregivers receive discharge instructions that include 
information on tasks required following discharge along 
with a diary to record daily symptoms and all information 
requested during the telephone calls or electronic surveys, 
including side effects (see supplemental file: follow-up 
surveys). Follow-up occurs daily until symptoms resolve or 
5 days, whichever occurs later, and again at 14 days and 1, 
3, 6, 9 and 12 months following enrolment. Data collected 
daily and at day 14 follow-up are used to measure efficacy 
and short-term safety outcomes. Long-term follow-up 
data (1 month onwards) are used to assess long-term 
adverse events, unanticipated medical encounters and 
development of new chronic illnesses in accordance to 
FDA guidelines (Guidance for Industry and Investigators: 
Safety Reporting and Requirements for INDs and BA/BE 
Studies).64 We use a standardised script and data collec-
tion forms to obtain follow-up information by telephone 
or via email survey. Follow-up procedures are centralised 
at the lead site. We also perform chart reviews to verify 
data regarding revisits, intravenous hydration, hospitalisa-
tion and microbiology testing using each centre’s medical 
record database. Personal data will be handled in compli-
ance of the Health Insurance Portability and Account-
ability Act. Data are entered in to encrypted and secure 
central databases managed by the DCC at the University 
of Utah, where state-of-the-art equipment and procedures 
ensure data quality and security.
Compliance
We assess patient compliance with therapy on day 5 and 
collect final data on day 14. To maximise compliance, 
caregivers are reminded of the importance and method 
of administering the probiotic/placebo. A similar scheme 
has been used in our previous studies.18 65–67
Probiotic quality control/independent testing
We test samples of all batches of probiotic product at an 
independent laboratory twice a year until expiration date 
to ensure adequate bacterial counts. In order to maxi-
mise bacterial viability, probiotic products are kept refrig-
erated at research pharmacies between 0°C and 4°C. 
Shipping and storage logs are retained.
Study monitoring
The DCC coordinated site (in-person and remote) moni-
toring as well as pharmacy monitoring at the beginning 
and once during the study. The monitor has provided 
each site with a written report, and sites have been 
required to respond to and resolve deficiencies. Spon-
soring and regulatory agency monitoring is at the discre-
tion of such agencies.
Outcome measures
The primary outcome to measure efficacy is the pres-
ence of moderate-to-severe AGE, as defined by a total 
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postenrolment MVS score ≥9 during the 2-week follow-up 
period (table 1). This scale has been validated in our 
patient populations.18 45 Each of the seven items in the 
scale is tabulated individually (maximum of 20 points); 
the sum of these individual variables represents the total 
MVS score. At the time of randomisation (time 0), a 
pre-enrolment MVS score is assigned based on symptoms 
prior to presentation. This score serves as a covariate in a 
secondary analysis of the primary outcome. The posten-
rolment MVS score used to determine the presence/
absence of the primary study outcome, is based only on 
symptoms that occur between time 0 (ie, randomisation) 
and the conclusion of the study period (ie, day 14). The 
postenrolment score is calculated only once, on day 14. 
At that time, each of the seven variables are assigned a 
score for the entire study period (time 0 to day 14). Each 
variable is scored in 1 of 3 methods: (1) worst 24 hours 
period—maximal number of episodes of vomiting in 
a 24-hour period, maximal number of episodes of diar-
rhoea in a 24-hour period and maximal temperature); (2) 
total duration of symptoms, including the number of days 
on which any gastroenteritis-related symptom occurred. 
For scoring purposes, the episode of AGE concludes 
after absence of symptoms for 24 hours; and (3) occur-
rence of an outcome—treatment and subsequent health-
care utilisation. A score of ≥9 defines moderate-to-severe 
disease because on the original score, severe disease was 
defined as ≥1168–72 and moderate as ≥9.73 In our deriva-
tion and validation pilot studies,18 45 construct validity 
was demonstrated and validated by using scores of ≥9 to 
define moderate and ≥11 to define severe disease. These 
cut-points were associated with significant increases in 
other measures of disease severity such as degree of dehy-
dration, likelihood of admission and daycare and parental 
work absenteeism.18 45
Main safety outcome
The main safety outcome is the occurrence of extraint-
estinal infection by the administered probiotic agent—
LGG. Based on previous human experience with LGG in 
healthy volunteers, pregnant women, neonates and chil-
dren with AGE, we do not anticipate that any extraintes-
tinal infections will occur. Adverse event analysis will follow 
FDA guidelines for assessment of attribution, toxicity 
grading scale and criteria for patient withdrawal. Per FDA 
recommendations, we conducted an interim safety anal-
ysis after the first 80 patients, including 40 less than 1 year 
of age, had completed their 1-month follow-up.
Secondary outcomes (efficacy)
Secondary outcomes include the following: (1) diarrhoea 
duration: time from treatment initiation until the appear-
ance of the last watery stool as reported during daily phone 
conversations, (2) vomiting duration, (3) return visits 
for unscheduled care to a healthcare provider related to 
vomiting, diarrhoea, dehydration, fever or fluid refusal, 
within 2 weeks of the index visit. We will not include 
scheduled visits (eg, reassessment, vaccinations and unre-
lated issues). This outcome is important because >50% of 
children with AGE have a follow-up office visit,16 8%–18% 
require an ED visit and 5%–8% are hospitalised.16 (4) Days 
of daycare missed by subjects, (5) days of work missed by 
caregivers and (6) household transmission rate: a house-
hold census is obtained at the time of enrolment, and we 
obtain information about incident household symptoms 
during the telephone follow-up calls. Secondary transmis-
sion is an integral feature of AGE, and households are 
relevant and well-established study units.74–76
Secondary outcomes (safety)
The secondary safety outcome is the presence of poten-
tial side effects such bloating, gas, intestinal rumbling, 
diarrhoea, blood in stool, abdominal pain, abdominal 
cramps, nausea, vomiting, loss of appetite, abnormal taste, 
heartburn, constipation, skin rash, fever, nasal conges-
tion, sore throat, cough, headache, malaise, muscle 
aches and chills. We acknowledge, however, that some 
toxicities will be difficult to distinguish from abdominal 
symptoms related to the AGE, and only at the time of data 
analysis will we be able to determine if these signs and 
symptoms differ between the groups (ie, by comparing 
the differences in occurrence between the active and 
placebo groups). The study physicians complete the 
appropriate form for all adverse events identified during 
the scheduled or unscheduled phone calls. During long-
term follow-up telephone calls (ie, those occurring after 
Table 1 Modified Vesikari Score
Points 0 1 2 3
Diarrhoea duration 0 1–96 hours 97–120 hours ≥121 hours
Max no. of diarrhoeal stools/24 hours 0 1–3 4–5 ≥6
Vomiting duration 0 1–24 hours 25–48 hours ≥49 hours
Max no. of vomiting episodes/24 hours 0 1 2–4 ≥5
Max recorded fever ≤37°C 37.1–38.4°C 38.5–38.9°C ≥39°C
Unscheduled healthcare visit 0 – Primary
care
Emergency
department
Treatment None Rehydration Hospital
admission
–
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14 days postenrolment), we inquire about unexpected 
events obligating medical attention and new onset of 
chronic disorders, especially those involving the digestive 
system.
Data analysis and sample size
All analyses will be undertaken by the ITT principle, 
except for side effects, which will use the ‘as-treated’ 
principle (compare the subjects based on the treatment 
regimen that they received). Patients who withdraw, 
drop out or crossover will be followed and included in 
the ITT analysis. All statistical tests of hypotheses will be 
two sided. For cases where information needed to derive 
the primary outcome is incomplete, we will use multiple 
imputation methods. The proportion of children with 
moderate-to-severe disease (ie, MVS ≥9), the primary 
outcome will be analysed by comparing proportions using 
a Mantel-Haenszel test, stratified by participating centre 
and duration of symptoms prior to presentation. Signif-
icance for this primary outcome measure will be set at 
0.05. Secondary analyses of the primary outcome will use 
logistic regression methods to adjust for covariates (eg, 
age, pre-enrolment MVS, hydration assessment and need 
for hospitalisation at index visit). We will also analyse the 
outcome using MVS as a continuous variable through a 
stratified Wilcoxon rank-sum test and compare the results 
with the primary analysis.
The overall significance level for statistical tests on the 
secondary outcomes will be set at 0.05. Holm’s method 
will be used to adjust for multiple comparisons.77 The 
continuous variables of durations of (1) diarrhoea and 
(2) vomiting will be measured in hours and analysed with 
a Van Elteren test78 and stratified by clinical centre and 
duration of symptoms. Similarly, the number of days (3) 
the child is absent from daycare and (4) the caregiver 
is absent from work will be analysed with a Van Elteren 
test, stratified by clinical centre and duration of symp-
toms. Dichotomous outcomes to be evaluated include ED 
AGE-related revisits, intravenous rehydration and hospi-
talisation. These six outcomes will be jointly assessed for 
significance using Holm’s method. Additional analyses 
involving these outcomes will include linear and logistic 
regression models that adjust for possible effects of base-
line characteristics. The proportions of children expe-
riencing (5) an unscheduled healthcare visit or (6) any 
potential adverse effect, as reported by the caregivers, will 
be compared between groups using the Mantel-Haenszel 
test, stratified by site and duration of symptoms. The anal-
ysis will evaluate the presence/absence of prespecified 
side effects, as an aggregate outcome variable. A per-pro-
tocol analysis will be conducted to provide additional 
insight as non-compliance may result in an underestima-
tion of the benefits of probiotics in the ITT analysis.79
Power analysis
The primary analysis will be performed on a binary 
outcome: development of moderate-to-severe disease. 
The power of this analysis depends on the proportion of 
patients with moderate-to-severe disease in each group 
considered. Data collected as part of our pilot evalu-
ations of the MVS in 729 children aged 3–48 months 
demonstrated that when using the ED visit as time 0, 25% 
of eligible children had scores consistent with moder-
ate-to-severe disease following discharge.18 45 This is a 
lower rate than previous reports of diarrhoea in paedi-
atric EDs69 70 and in the community68 71 73 but is attributed 
to our exclusion of symptoms that existed prior to the 
visit. Because both the populations and method of MVS 
calculation in the MVS derivation and validation studies 
and the current proposal are identical, 25% is supported 
by data from our pilot study and is likely to be accurate. 
To determine the minimal clinically important difference 
that we should aim to detect, 10 content experts were 
surveyed. Absolute risk differences ranging from 7.5% to 
15% were suggested. We selected a conservative estimate 
of 10% for the primary outcome (ie, number needed to 
treat of 10). For the current study, our sample size calcu-
lation assumed a 25% event rate in the control group, 
and we desire to detect an absolute beneficial treatment 
effect of 10% with 90% power. Using a two-sided type 
I error (α) of 0.05 and the hypothesised proportions 
yields a required total sample size of 670 patients.80 Our 
expected power, if true event rates in our two groups 
differ from those expected, is presented in table 2. Based 
on prior work by our group,18 45 65 81 82 we assumed 10% 
loss to follow-up (adjustment: 670/0.90=744), 5% drop 
out and 3% drop in rate (caregivers who buy a probi-
otic agent to administer to their child) (adjustment: 
744/ (0.92)2=879). Adjustment for O’Brien-Fleming 
monitoring boundaries requires a further 2% increase. 
Thus, the total number randomised (final sample size) 
is therefore 900. In the fall of 2015, however, 36 patients 
were potentially exposed to a batch of LGG that was later 
found to contain inadequate bacterial counts on inde-
pendent testing. We assumed that approximately 18 of 
these were exposed and having the same effect as drop-
outs. In order to maintain study power under this worst-
case scenario, we would have to increase the sample size 
to 970 patients (900/(0.963)2, where 0.963 is 1 minus 
Table 2 Power analysis. 
Outcome 
control
Outcome 
intervention % Difference Power
0.30 0.21 9 0.76
0.30 0.20 10 0.85
0.25 0.15 10 0.90
0.25 0.16 9 0.82
0.25 0.17 8 0.72
0.20 0.10 10 0.95
0.20 0.12 8 0.81
0.20 0.13 7 0.69
Highlighted area corresponds to stated assumptions  in the text.
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the drop-out rate of 18/485=0.037). Based on prelimi-
nary surveys, we believe that achieving this sample size is 
feasible at our sites.
(1) Formal subgroup analyses will be based on (a) 
age <1 year, (b) antibiotic usage, (c) infectious agent 
(virus, bacteria, parasite or other). Treatment effect 
will be summarised across subgroups. A subgroup effect 
will be declared to be significant only if the interaction 
between treatment and the subgroup factor is signifi-
cant in an appropriate statistical model (including multi-
variate regression analyses), using a significance level 
of <0.05/3=0.017 for each. (2) Duration of vomiting will 
be analysed only in those subjects reporting ≥3 episodes 
of vomiting in the 24 hours preceding enrolment. (3) 
Daycare and work absenteeism will only be analysed for 
those subjects who attend daycare and/or whose care-
givers work outside of the home.
Enrichment design
The above study design and power analysis are based on 
the assumption of homogeneous treatment effect. We 
incorporated an enrichment design83 84 to restore the 
statistical power if a subpopulation with a substantially 
low treatment effect is identified. We are particularly 
interested in two potential subpopulations: participants 
with <2 days of symptoms and those with ≥2 days of 
symptoms. Based on our pilot data, each subpopulation 
accounts for approximately 50% of the total popula-
tion. The decision for enrolment modification was made 
at the first interim analysis for efficacy (350 enrolled 
patients). Specifically, three statistics (based on a normal 
approximation of binomial distribution or z-statis-
tics) were calculated to compare the primary endpoint 
between treatment and control groups for subjects in 
the total population and the two subpopulations, respec-
tively. If the z-statistic from a subpopulation is <0.3 and 
also smaller than that in the total population, subjects 
from this subpopulation are no longer to be considered 
in the subsequent enrolment. All subjects, regardless of 
symptom duration are to be included in the final anal-
yses. Our simulation studies have showed that such an 
enrichment design can increase the power considerably 
when the treatment effects are different across subpop-
ulations, while it will have little impact on power when 
the treatment effects are similar. Following these analyses 
performed after 350 patients were enrolled and recom-
mendations by the DSMB, the decision not to modify 
enrolment was made.
Frequency of analysis
The DSMB met after 80 (safety at 1 month), 350 and 650 
subjects had completed their 1-month follow-up assess-
ments to review enrolment, study procedures, case report 
form completion, data quality, loss to follow-up, drop-in 
rate and interim safety and efficacy results. The analyses 
tested the hypothesis that the probability of developing 
moderate-to-severe AGE in the probiotic arm is equal to 
that in the placebo arm. Conservative O’Brien-Fleming 
monitoring boundaries, implemented using the Lan-De-
Mets alpha spending function approach, will be used as 
guidelines for early stopping for efficacy. At each step, 
the DSMB recommended that the study continue without 
modifications (table 3).
Ethics and dissemination
This trial is being conducted under an Investigational 
New Drug application approved by the FDA (Investiga-
tional New Drug application 15371). Institutional review 
board (IRB) approval has been obtained at all sites. 
Financial compensation is provided to compensate for 
parents’ time completing follow-up. This compensation 
was approved by each site’s IRB. All important modifica-
tions will be communicated to the pertinent parties. Data 
use agreements have been obtained between all sites, 
and the DCC and Material use agreements have been 
obtained between all sites and the lead site. The results 
of the study will be published in peer-reviewed journals. 
A deidentified public data set will be made available after 
the completion of all study procedures. The study inves-
tigators will have access to the final trial data set. Author-
ship will be conferred per the International Committee of 
Medical Journal Editors.
dIsCussIon
This is the largest RCT of probiotics in children 
presenting with AGE to an ED to date. We propose 
to improve outcomes in children affected by AGE by 
modifying the disease process through biologically plau-
sible mechanisms. Translating this knowledge into a 
disease-modifying clinical intervention would represent 
a major change in the approach to this burdensome 
illness and provide clarity to clinical practice that has 
been hindered by aggressive marketing in the absence of 
valid data. Critical elements incorporated into our design 
that were absent in earlier studies are: (1) evaluating a 
specific regimen in a large number of participants in a 
Table 3 Interim analyses stopping rules
Analysis Two-sided p Value
Probability of stopping
(80% power) (%)
Probability of stopping
(90% power) (%)
First (350 patients) <0.0007 4.9 8.5
Second (620 patients) <0.014 40.2 51.2
Final <0.046 34.9 30.4
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geographically diverse network in the USA, (2) using a 
meaningful and validated outcome in our population, (3) 
identifying infectious causes, (4) using adaptive randomi-
sation to target specific subgroups and (5) accounting for 
pre-evaluation administration of probiotics. We attempt to 
minimise bias by adhering to the 2013 SPIRIT guidelines 
and the 2010 CONSORT Statement recommendations 
including the use of ‘third-party’ assignment.38 Placebo 
capsules and active drug are provided by I-Health Inc. 
The probiotic and placebo capsules and powder are iden-
tical in appearance, taste, texture and odour. Participants, 
families, healthcare providers, data collectors, outcome 
adjudicators and data analysts are blinded as to inter-
vention arm, thereby preventing bias in outcome assess-
ment. An ITT analysis will be performed to minimise 
bias associated with poor compliance and non-random 
loss of participants.85 Cointerventions (eg, antiemetic 
administration and intravenous rehydration) and other 
potential sources of confounding are recorded. Our use 
of a published validated score as an outcome measure 
protects against the introduction of bias in the assessment 
of treatment effects.86
Of note, a similar study using a different probiotic 
product containing Lactobacillus rhamnosus and L. helveticus 
(Lacidofil) is being conducted in Canada with funding 
from the Canadian Institutes of Health Research.87 This 
parallel study provides opportunities to enhance our 
knowledge about the effect of probiotics in children with 
AGE.
ConClusIon
This double-blind, placebo-controlled RCT will quan-
tify the benefits and potential side effects associated 
with probiotic administration in ambulatory children 
presenting to the ED with AGE. This will provide the first 
definitive evidence in the USA for or against using probi-
otic therapy for this condition and establish the safety of 
the intervention. The results of this multicentre study will 
guide the standard of care: if probiotic administration is 
associated with benefit, it offers a relatively inexpensive 
and safe to administer treatment to reduce morbidity 
from AGE. If the trial does not demonstrate probiotic 
efficacy, healthcare and family and societal resources may 
be refocused on different interventions.
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